subscribeSubscribe
Genprex ExpandsTrial Sites for Acclaim-3 Study with Tecentriq to Treat SCLC

Genprex ExpandsTrial Sites for Acclaim-3 Study with Tecentriq to Treat SCLC
PR NEWSWIRE
03 Apr 2024
Share Share
Gritstone ground down by phase 2 cancer vaccine fail

Gritstone ground down by phase 2 cancer vaccine fail
Nick Paul Taylor FIERCE BIOTECH
01 Apr 2024
Share Share
Bristol Myers reveals subcutaneous Opdivo data in kidney cancer as I-O battle heads to new front

Bristol Myers reveals subcutaneous Opdivo data in kidney cancer as I-O battle heads to new front

FIERCE PHARMA
30 Jan 2024
Share Share
Roche and Exelixis detail rare success for Cabometyx-Tecentriq combo in prostate cancer

Roche and Exelixis detail rare success for Cabometyx-Tecentriq combo in prostate cancer
ENDPTS
26 Jan 2024
Share Share
Roche’s Tecentriq SC receives EC approval for cancer treatment

Roche’s Tecentriq SC receives EC approval for cancer treatment
PHARMACEUTICAL TECHNOLOGY
17 Jan 2024
Share Share
Affimed Announces Positive Data for AFM24 in Combination with Atezolizumab

Affimed Announces Positive Data for AFM24 in Combination with Atezolizumab
GLOBENEWSWIRE
11 Dec 2023
Share Share
Oncolytics Announces Phase 1/2 Study of Pelareorep Has Met Criteria for Efficacy

Oncolytics Announces Phase 1/2 Study of Pelareorep Has Met Criteria for Efficacy
PR NEWSWIRE
09 Nov 2023
Share Share
Roche hits FDA delay with subcutaneous Tecentriq

Roche hits FDA delay with subcutaneous Tecentriq
Angus Liu FIERCE PHARMA
07 Sep 2023
Share Share
Atezolizumab Plus Chemotherapy Demonstrates Intracranial Activity in NSCLC

Atezolizumab Plus Chemotherapy Demonstrates Intracranial Activity in NSCLC
ONCLIVE
01 Sep 2023
Share Share
England to rollout world-first seven-minute cancer treatment jab

England to rollout world-first seven-minute cancer treatment jab
REUTERS
30 Aug 2023
Share Share